New Cancer Immunotherapy Agents in Development: A report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Prasad S. Adusumilli; Edward Cha; Mark Cornfeld; Thomas Davis; Adi Diab; Thomas W. Dubensky; Elizabeth Evans; Jane L. Grogan; Bryan A. Irving; Rom S. Leidner; Shane A. Olwill; Patrick Soon-Shiong; Frederic Triebel; David Tuck; Adrian Bot; Roger D. Dansey; Charles G. Drake; Gordon J. Freeman; Ramy Ibrahim; Salil Patel; Daniel S. Chen

doi:10.1186/s40425-017-0253-2

New Cancer Immunotherapy Agents in Development: A report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil PatelDaniel S. Chen

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

Original language	English (US)
Article number	50
Journal	Journal for immunotherapy of cancer
Volume	5
Issue number	1
DOIs	https://doi.org/10.1186/s40425-017-0253-2
State	Published - Jun 20 2017

Keywords

Cancer
Checkpoint inhibitors
Combination therapy
Immunotherapy
PD-1

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1186/s40425-017-0253-2

Cite this

Adusumilli, P. S., Cha, E., Cornfeld, M., Davis, T., Diab, A., Dubensky, T. W., Evans, E., Grogan, J. L., Irving, B. A., Leidner, R. S., Olwill, S. A., Soon-Shiong, P., Triebel, F., Tuck, D., Bot, A., Dansey, R. D., Drake, C. G., Freeman, G. J., Ibrahim, R., ... Chen, D. S. (2017). New Cancer Immunotherapy Agents in Development: A report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. Journal for immunotherapy of cancer, 5(1), Article 50. https://doi.org/10.1186/s40425-017-0253-2

Adusumilli, PS, Cha, E, Cornfeld, M, Davis, T, Diab, A, Dubensky, TW, Evans, E, Grogan, JL, Irving, BA, Leidner, RS, Olwill, SA, Soon-Shiong, P, Triebel, F, Tuck, D, Bot, A, Dansey, RD, Drake, CG, Freeman, GJ, Ibrahim, R, Patel, S & Chen, DS 2017, 'New Cancer Immunotherapy Agents in Development: A report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016', Journal for immunotherapy of cancer, vol. 5, no. 1, 50. https://doi.org/10.1186/s40425-017-0253-2

@article{49967437f07c4eccb1517ddd72915cbf,

title = "New Cancer Immunotherapy Agents in Development: A report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016",

abstract = "This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.",

keywords = "Cancer, Checkpoint inhibitors, Combination therapy, Immunotherapy, PD-1",

author = "Adusumilli, {Prasad S.} and Edward Cha and Mark Cornfeld and Thomas Davis and Adi Diab and Dubensky, {Thomas W.} and Elizabeth Evans and Grogan, {Jane L.} and Irving, {Bryan A.} and Leidner, {Rom S.} and Olwill, {Shane A.} and Patrick Soon-Shiong and Frederic Triebel and David Tuck and Adrian Bot and Dansey, {Roger D.} and Drake, {Charles G.} and Freeman, {Gordon J.} and Ramy Ibrahim and Salil Patel and Chen, {Daniel S.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = jun,

day = "20",

doi = "10.1186/s40425-017-0253-2",

language = "English (US)",

volume = "5",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - New Cancer Immunotherapy Agents in Development

T2 - A report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

AU - Adusumilli, Prasad S.

AU - Cha, Edward

AU - Cornfeld, Mark

AU - Davis, Thomas

AU - Diab, Adi

AU - Dubensky, Thomas W.

AU - Evans, Elizabeth

AU - Grogan, Jane L.

AU - Irving, Bryan A.

AU - Leidner, Rom S.

AU - Olwill, Shane A.

AU - Soon-Shiong, Patrick

AU - Triebel, Frederic

AU - Tuck, David

AU - Bot, Adrian

AU - Dansey, Roger D.

AU - Drake, Charles G.

AU - Freeman, Gordon J.

AU - Ibrahim, Ramy

AU - Patel, Salil

AU - Chen, Daniel S.

PY - 2017/6/20

Y1 - 2017/6/20

N2 - This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

AB - This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

KW - Cancer

KW - Checkpoint inhibitors

KW - Combination therapy

KW - Immunotherapy

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85021065315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021065315&partnerID=8YFLogxK

U2 - 10.1186/s40425-017-0253-2

DO - 10.1186/s40425-017-0253-2

M3 - Review article

C2 - 28649381

AN - SCOPUS:85021065315

SN - 2051-1426

VL - 5

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 1

M1 - 50

ER -